Zhongmou Therapeutics is a global clinical-stage biotechnology company focused on restoring vision for millions affected by blindness-causing ocular diseases. Leveraging 20+ years of pioneering gene therapy research, Zhongmou has advanced from lab research to clinical applications, delivering sight-restoring breakthroughs. The company utilizes a robust AAV vector platform and cutting-edge optogenetic therapies to develop a diverse product pipeline targeting significant unmet needs. Zhongmou's innovations include China's first gene therapy for retinal splitting and leading optogenetic therapies featuring photosensitive proteins, solidifying its leadership in the ophthalmic field. These groundbreaking therapies push the boundaries of science and aim to improve public health outcomes through advanced medical innovation.
Company Details
- Employees
- 10
- Founded
- -
- Address
- Central And Western Building C4, Guanggu Biocity, Gaoxin Avenue, East Lake Hi-Tech Zone, Floor 4,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://zmtherapeutics.com
- Keywords
- Hope Medicine Inc.
- HQ
- Wuhan, Hubei province
Zhongmou Therapeutics Questions
Zhongmou Therapeutics's website is http://zmtherapeutics.com
Zhongmou Therapeutics's LinkedIn profile is https://cn.linkedin.com/company/zmtherapeutics
Zhongmou Therapeutics has
10 employees.
View email and phone details for 10
employees at Zhongmou Therapeutics.
Zhongmou Therapeutics's industry is
Biotechnology Research
Zhongmou Therapeutics's top competitors are
Ascletis Pharma Inc.,
Askbio Inc.,
Nextleap,
My Qr Code,
Huidagene Therapeutics,
Tcbalance Biopharmaceuticals,
Saral Patro,
Dnali Data Technologies,
Hope Medicine Inc,
Myqrcode.
Zhongmou Therapeutics's categories are Biotechnology Research
Zhongmou Therapeutics's founding year is 2019
